RZLT
Rezolute, Inc.
Biotechnology
Market Cap$295M
5Y Perf.-13.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
RZLT vs VNDA vs PTCT vs ACAD
Revenue, margins, valuation, and 5-year total return — side by side.
VNDA
Vanda Pharmaceuticals Inc.
Biotechnology
Market Cap$378M
5Y Perf.-45.5%
PTCT
PTC Therapeutics, Inc.
Biotechnology
Market Cap$5.35B
5Y Perf.+27.2%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.86B
5Y Perf.-54.6%
RZLT vs VNDA vs PTCT vs ACAD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RZLT | VNDA | PTCT | ACAD |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $295M | $378M | $5.35B | $3.86B |
| Revenue (TTM) | $0.00 | $218M | $827M | $1.10B |
| Net Income (TTM) | $-84M | $-240M | $-187M | $376M |
| Gross Margin | — | 71.1% | 49.7% | 91.5% |
| Operating Margin | — | -73.6% | -8.3% | 7.4% |
| Forward P/E | — | — | 8.3x | 50.9x |
| Total Debt | $2M | $13M | $492M | $52M |
| Cash & Equiv. | $94M | $85M | $985M | $178M |
RZLT vs VNDA vs PTCT vs ACAD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RZLT
VNDA
PTCT
ACAD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Rezolute, Inc. (RZLT) | 100 | 87.0 | -13.0% |
| Vanda Pharmaceutica… (VNDA) | 100 | 54.5 | -45.5% |
| PTC Therapeutics, I… (PTCT) | 100 | 127.2 | +27.2% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 45.4 | -54.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RZLT vs VNDA vs PTCT vs ACAD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PTCT leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. ACADIA Pharmaceuticals Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. RZLT also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
RZLT
Rezolute, Inc.
The Income Pick
RZLT is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.79
- Lower volatility, beta 0.79, Low D/E 1.0%, current ratio 14.37x
- Beta 0.79, current ratio 14.37x
- Beta 0.79 vs ACAD's 1.26, lower leverage
Best for: income & stability and sleep-well-at-night
VNDA
Vanda Pharmaceuticals Inc.
The Secondary Option
VNDA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
PTCT
PTC Therapeutics, Inc.
The Growth Play
PTCT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 114.5%, EPS growth 264.5%, 3Y rev CAGR 35.3%
- 7.3% 10Y total return vs ACAD's -22.9%
- 114.5% revenue growth vs RZLT's -18.4%
- Lower P/E (8.3x vs 50.9x)
Best for: growth exposure and long-term compounding
ACAD
ACADIA Pharmaceuticals Inc.
The Quality Compounder
ACAD is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 34.3% margin vs VNDA's -110.0%
- 26.2% ROA vs RZLT's -60.8%, ROIC 10.0% vs -97.9%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PTCT | 114.5% revenue growth vs RZLT's -18.4% |
| Value | PTCT | Lower P/E (8.3x vs 50.9x) |
| Quality / Margins | ACAD | 34.3% margin vs VNDA's -110.0% |
| Stability / Safety | RZLT | Beta 0.79 vs ACAD's 1.26, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | PTCT | +58.2% vs RZLT's -14.4% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs RZLT's -60.8%, ROIC 10.0% vs -97.9% |
RZLT vs VNDA vs PTCT vs ACAD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2018
RZLT vs VNDA vs PTCT vs ACAD — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLACADLAGGINGPTCT
Who Leads Where
ACAD leads in 1 of 6 categories
RZLT leads 0 • VNDA leads 0 • PTCT leads 0 • 4 tied
Explore the data ↓PTCTPTC Therapeutics, Inc.
0leads
VNDAVanda Pharmaceuticals…
0leads
RZLTRezolute, Inc.
0leads
ACADACADIA Pharmaceutical…
1leads
6 Total Categories
CATEGORYLEADERvs RZLTvs VNDAMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ACAD5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ACAD leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ACAD and RZLT operate at a comparable scale, with $1.1B and $0 in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to VNDA's -110.0%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $218M | $827M | $1.1B |
| EBITDAEarnings before interest/tax | -$64M | -$150M | -$37M | $96M |
| Net IncomeAfter-tax profit | -$84M | -$240M | -$187M | $376M |
| Free Cash FlowCash after capex | -$77M | -$127M | -$229M | $212M |
| Gross MarginGross profit ÷ Revenue | — | +71.1% | +49.7% | +91.5% |
| Operating MarginEBIT ÷ Revenue | — | -73.6% | -8.3% | +7.4% |
| Net MarginNet income ÷ Revenue | — | -110.0% | -22.6% | +34.3% |
| FCF MarginFCF ÷ Revenue | — | -58.5% | -27.7% | +19.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +3.4% | -76.8% | +9.7% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | -64.0% | -100.3% | -81.8% |
ACAD leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — VNDA and PTCT each lead in 2 of 5 comparable metrics.
Valuation Metrics
At 8.3x trailing earnings, PTCT trades at a 16% valuation discount to ACAD's 9.9x P/E. On an enterprise value basis, PTCT's 5.4x EV/EBITDA is more attractive than ACAD's 26.9x.
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $295M | $378M | $5.3B | $3.9B |
| Enterprise ValueMkt cap + debt − cash | $203M | $305M | $4.9B | $3.7B |
| Trailing P/EPrice ÷ TTM EPS | -3.15x | -1.71x | 8.29x | 9.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 50.91x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 5.42x | 26.91x |
| Price / SalesMarket cap ÷ Revenue | — | 1.75x | 3.09x | 3.61x |
| Price / BookPrice ÷ Book value/share | 1.45x | 1.15x | — | 3.15x |
| Price / FCFMarket cap ÷ FCF | — | — | 7.61x | 36.74x |
Evenly matched — VNDA and PTCT each lead in 2 of 5 comparable metrics.
Profitability & Efficiency
Evenly matched — PTCT and ACAD each lead in 3 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-66 for RZLT. RZLT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to ACAD's 0.04x. On the Piotroski fundamental quality scale (0–9), PTCT scores 7/9 vs VNDA's 2/9, reflecting strong financial health.
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -65.8% | -61.4% | — | +35.6% |
| ROA (TTM)Return on assets | -60.8% | -44.6% | -6.8% | +26.2% |
| ROICReturn on invested capital | -97.9% | -32.2% | — | +10.0% |
| ROCEReturn on capital employed | -55.7% | -33.6% | +55.9% | +10.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 7 | 6 |
| Debt / EquityFinancial leverage | 0.01x | 0.04x | — | 0.04x |
| Net DebtTotal debt minus cash | -$92M | -$72M | -$492M | -$126M |
| Cash & Equiv.Liquid assets | $94M | $85M | $985M | $178M |
| Total DebtShort + long-term debt | $2M | $13M | $492M | $52M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -1.67x | — |
Evenly matched — PTCT and ACAD each lead in 3 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — RZLT and PTCT each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTCT five years ago would be worth $16,026 today (with dividends reinvested), compared to $3,578 for VNDA. Over the past 12 months, PTCT leads with a +58.2% total return vs RZLT's -14.4%. The 3-year compound annual growth rate (CAGR) favors RZLT at 9.9% vs VNDA's -2.7% — a key indicator of consistent wealth creation.
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +42.7% | -22.5% | -16.0% | -13.7% |
| 1-Year ReturnPast 12 months | -14.4% | +45.9% | +58.2% | +52.4% |
| 3-Year ReturnCumulative with dividends | +32.6% | -7.8% | +16.1% | +4.7% |
| 5-Year ReturnCumulative with dividends | -52.5% | -64.2% | +60.3% | +7.1% |
| 10-Year ReturnCumulative with dividends | -93.6% | -26.8% | +733.2% | -22.9% |
| CAGR (3Y)Annualised 3-year return | +9.9% | -2.7% | +5.1% | +1.5% |
Evenly matched — RZLT and PTCT each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RZLT and ACAD each lead in 1 of 2 comparable metrics.
Risk & Volatility
RZLT is the less volatile stock with a 0.79 beta — it tends to amplify market swings less than ACAD's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ACAD currently trades 81.1% from its 52-week high vs RZLT's 27.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 1.04x | 1.13x | 1.26x |
| 52-Week HighHighest price in past year | $11.46 | $9.94 | $87.50 | $27.81 |
| 52-Week LowLowest price in past year | $1.07 | $3.81 | $37.94 | $14.45 |
| % of 52W HighCurrent price vs 52-week peak | +27.0% | +64.3% | +73.7% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 46.2 | 54.9 | 45.3 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 2.2M | 1.6M | 1.0M | 1.8M |
Evenly matched — RZLT and ACAD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RZLT as "Buy", VNDA as "Buy", PTCT as "Buy", ACAD as "Buy". Consensus price targets imply 121.8% upside for VNDA (target: $14) vs 39.0% for PTCT (target: $90).
| Metric | RZLTRezolute, Inc. | VNDAVanda Pharmaceuti… | PTCTPTC Therapeutics,… | ACADACADIA Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $6.33 | $14.17 | $89.67 | $34.78 |
| # AnalystsCovering analysts | 12 | 19 | 26 | 37 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ACAD leads in 1 of 6 categories — strongest in Income & Cash Flow. 4 categories are tied.
Best OverallACADIA Pharmaceuticals Inc. (ACAD)Leads 1 of 6 categories
Loading custom metrics...
RZLT vs VNDA vs PTCT vs ACAD: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RZLT or VNDA or PTCT or ACAD a better buy right now?
For growth investors, PTC Therapeutics, Inc.
(PTCT) is the stronger pick with 114. 5% revenue growth year-over-year, versus 8. 7% for Vanda Pharmaceuticals Inc. (VNDA). PTC Therapeutics, Inc. (PTCT) offers the better valuation at 8. 3x trailing P/E, making it the more compelling value choice. Analysts rate Rezolute, Inc. (RZLT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RZLT or VNDA or PTCT or ACAD?
On trailing P/E, PTC Therapeutics, Inc.
(PTCT) is the cheapest at 8. 3x versus ACADIA Pharmaceuticals Inc. at 9. 9x.
03Which is the better long-term investment — RZLT or VNDA or PTCT or ACAD?
Over the past 5 years, PTC Therapeutics, Inc.
(PTCT) delivered a total return of +60. 3%, compared to -64. 2% for Vanda Pharmaceuticals Inc. (VNDA). Over 10 years, the gap is even starker: PTCT returned +733. 2% versus RZLT's -93. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RZLT or VNDA or PTCT or ACAD?
By beta (market sensitivity over 5 years), Rezolute, Inc.
(RZLT) is the lower-risk stock at 0. 79β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 60% more volatile than RZLT relative to the S&P 500. On balance sheet safety, Rezolute, Inc. (RZLT) carries a lower debt/equity ratio of 1% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — RZLT or VNDA or PTCT or ACAD?
By revenue growth (latest reported year), PTC Therapeutics, Inc.
(PTCT) is pulling ahead at 114. 5% versus 8. 7% for Vanda Pharmaceuticals Inc. (VNDA). On earnings-per-share growth, the picture is similar: PTC Therapeutics, Inc. grew EPS 264. 5% year-over-year, compared to -1068. 8% for Vanda Pharmaceuticals Inc.. Over a 3-year CAGR, PTCT leads at 35. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RZLT or VNDA or PTCT or ACAD?
PTC Therapeutics, Inc.
(PTCT) is the more profitable company, earning 39. 4% net margin versus -102. 0% for Vanda Pharmaceuticals Inc. — meaning it keeps 39. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PTCT leads at 49. 5% versus -70. 0% for VNDA. At the gross margin level — before operating expenses — PTCT leads at 95. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RZLT or VNDA or PTCT or ACAD more undervalued right now?
Analyst consensus price targets imply the most upside for VNDA: 121.
8% to $14. 17.
08Which pays a better dividend — RZLT or VNDA or PTCT or ACAD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is RZLT or VNDA or PTCT or ACAD better for a retirement portfolio?
For long-horizon retirement investors, PTC Therapeutics, Inc.
(PTCT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13), +733. 2% 10Y return). Both have compounded well over 10 years (PTCT: +733. 2%, ACAD: -22. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RZLT and VNDA and PTCT and ACAD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RZLT is a small-cap quality compounder stock; VNDA is a small-cap quality compounder stock; PTCT is a small-cap high-growth stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.